Dihydrotestosterone as a Protective Agent in Chronic Experimental Autoimmune Encephalomyelitis

Area of Science:

• Neuroimmunology
• Endocrinology
• Experimental Neurology

Background:

• Multiple sclerosis (MS) is a chronic central nervous system inflammatory disease.
• Hormonal variations, particularly low testosterone in males, may influence MS susceptibility and progression.
• Testosterone exhibits protective effects in experimental autoimmune encephalomyelitis (EAE), a common MS model.

Purpose of the Study:

• To investigate the therapeutic potential of dihydrotestosterone (DHT) in a chronic relapsing EAE rat model.
• To determine if DHT administration can mitigate disease severity and underlying pathological processes in EAE.

Main Methods:

• Utilized Dark Agouti rats, an experimental model for chronic relapsing EAE.
• Administered DHT and assessed clinical scores, spinal cord pathology, inflammation markers, oxidative stress, and mitochondrial activity 45 days post-EAE induction.
• Analyzed levels of DHT metabolites to ascertain the primary active compound.

Main Results:

• DHT treatment significantly improved clinical scores in EAE rats.
• Reduced spinal cord gliosis, inflammation (GFAP, MHC-II, TSPO, IL-1β, TLR4, NF-κB), and oxidative stress (TBARS, Bax).
• Improved mitochondrial DNA and protein content, indicating enhanced mitochondrial function.

Conclusions:

• DHT demonstrates significant neuroprotective and anti-inflammatory effects in a chronic EAE model.
• DHT itself, rather than its metabolites, appears responsible for the observed therapeutic benefits.
• DHT presents a promising therapeutic avenue for managing chronic multiple sclerosis.